Phenoxybenzamine is presented for historical perspective; it no longer indicated in clinical treatment of BPH. A long-acting, nonselective a-blocker with affinity for both a1- and a2-receptors, its current indication is for treatment of hypertension and sweating associated with pheochromocytoma. Demonstrable pharmacologic effects may persist for 3-4 d after intravenous administration (19).
Early studies of phenoxybenzamine demonstrated therapeutic effect in patients with BPH-associated voiding symptoms. In two large reviews, 80-90% of treated patients reported symptomatic improvement (20,21). Maximum urinary flow rate improvements were noted as well. Significant adverse effects occurred in approx 30% of treated
Summary of a-Antagonists in Current Clinical Use for the Treatment of Male LUTS
Was this article helpful?
Do You Suffer From High Blood Pressure? Do You Feel Like This Silent Killer Might Be Stalking You? Have you been diagnosed or pre-hypertension and hypertension? Then JOIN THE CROWD Nearly 1 in 3 adults in the United States suffer from High Blood Pressure and only 1 in 3 adults are actually aware that they have it.